
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems is facing reimbursement challenges for its Inspire system, leading to a lowered revenue guidance range for 2026. However, management expects a return to revenue growth in 2027, and revenue is expected to reach $888 million in 2027, a 6% increase from the new 2026 revenue estimate of $838 million. The company's profitability may be impacted by these challenges, but the potential introduction of the Inspire 5 product could increase demand for the company's offerings. As a result, while fiscal year 2026 may be uncertain, there is potential for future growth and profitability in the long term.
Bears say
Inspire Medical Systems is facing numerous challenges, such as declining revenue due to reimbursement coding uncertainty and competition from other medical devices. The company recently cut its 2026 revenue guidance by $125M, leading to negative year-over-year growth expectations for Q3 and Q4. While it has a strong cash position and a dominant market position, there are concerns about its credibility and execution. The company may require a multi-quarter turnaround to overcome these challenges, making it a risky investment.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares